eXalt2 and eXalt3 are clinical research studies evaluating an investigational medication, X-396, for adults with a type of non-small cell lung cancer (NSCLC) that is called ALK positive. ALK is short for anaplastic lymphoma kinase. ALK is a gene that can change and affect the way that the lung cancer develops and grows. X-396 is thought to potentially block the effects of the ALK gene in NSCLC.
The eXalt2 study is a Phase 2 study evaluating X-396 as a potential treatment for patients with ALK-positive NSCLC who have previously received treatment for the disease. The eXalt3 study is a Phase 3 study evaluating the therapeutic potential of X-396 in treatment-naive patients with ALK-positive NSCLC.
If you have NSCLC that is ALK positive, you may be eligible to participate in the eXalt2 study or the eXalt3 study. Are you interested in learning more about the eXalt2 clinical research study or the eXalt3 clinical research study?
Xcovery is currently supporting investigator-led expanded access for individual patients, including for emergency use (also referred to as single patient INDs), for patients without other appropriate treatment options. Please contact firstname.lastname@example.org for additional information.